Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Volker Brinkmann

Showing results (1-10 of 173) with videos related to

Pageof 18
Sort By:
British Journal of Pharmacology|October 10, 2009
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous systemVolker Brinkmann
Pharmacology & Therapeutics|June 15, 2007
Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacologyVolker Brinkmann
Journal of Innate Immunity|June 18, 2018
Neutrophil Extracellular Traps in the Second DecadeVolker Brinkmann
Yonsei Medical Journal|January 1, 2005
FTY720: mechanism of action and potential benefit in organ transplantationVolker Brinkmann
Nature Reviews. Immunology|September 28, 2021
Entering the neutrophil trapVolker Brinkmann, Arturo Zychlinsky
The Journal of Cell Biology|September 5, 2012
Neutrophil extracellular traps: is immunity the second function of chromatin?Volker Brinkmann, Arturo Zychlinsky
Discovery Medicine|September 30, 2011
A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya)Jerold Chun, Volker Brinkmann
Nature Reviews. Microbiology|July 17, 2007
Beneficial suicide: why neutrophils die to make NETsVolker Brinkmann, Arturo Zychlinsky
Neurology|February 23, 2011
Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulationTimothy Hla, Volker Brinkmann
Current Opinion in Pharmacology|March 28, 2006
Pulmonary and vascular pharmacology of sphingosine 1-phosphateVolker Brinkmann, Thomas Baumruker
Pageof 18

Showing results (1-10 of 173) with videos related to

Sort By:
Pageof 18
British Journal of Pharmacology|October 10, 2009
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous systemVolker Brinkmann
Pharmacology & Therapeutics|June 15, 2007
Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacologyVolker Brinkmann
Journal of Innate Immunity|June 18, 2018
Neutrophil Extracellular Traps in the Second DecadeVolker Brinkmann
Yonsei Medical Journal|January 1, 2005
FTY720: mechanism of action and potential benefit in organ transplantationVolker Brinkmann
Nature Reviews. Immunology|September 28, 2021
Entering the neutrophil trapVolker Brinkmann, Arturo Zychlinsky
The Journal of Cell Biology|September 5, 2012
Neutrophil extracellular traps: is immunity the second function of chromatin?Volker Brinkmann, Arturo Zychlinsky
Discovery Medicine|September 30, 2011
A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya)Jerold Chun, Volker Brinkmann
Nature Reviews. Microbiology|July 17, 2007
Beneficial suicide: why neutrophils die to make NETsVolker Brinkmann, Arturo Zychlinsky
Neurology|February 23, 2011
Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulationTimothy Hla, Volker Brinkmann
Current Opinion in Pharmacology|March 28, 2006
Pulmonary and vascular pharmacology of sphingosine 1-phosphateVolker Brinkmann, Thomas Baumruker
Pageof 18